Co-Trimoxazole
Composition
The formulation contains Sulfamethoxazole 400 mg and Trimethoprim 80 mg with microcrystalline cellulose, povidone, sodium starch glycolate, and magnesium stearate as the active ingredient.
Indications
Indicated for the treatment of bacterial infections such as urinary tract infections, respiratory tract infections, gastrointestinal infections, and Pneumocystis jirovecii pneumonia.
Side effects
Common side effects include nausea, vomiting, rash, hyperkalemia, and in rare cases, serious skin reactions and blood disorders.
Precautions
Monitor blood counts and renal function; use with caution in patients with folate deficiency, severe renal or hepatic impairment, or G6PD deficiency; ensure adequate hydration to prevent crystalluria.
Contraindications
Liver disease, severe renal disease, late pregnancy, infants
Dosage and administration
One tablet every 12 hours for 5 to 14 days, adjust based on infection
Countries
UK, Canada, India, Australia
Available Forms
Tablets, oral suspension, injectable form
Manufacturing Services
Third Party Manufacturing Company WHO, GMP, EUGMP, USFDA, In India | Contract Manufacturing Organization (CMO) WHO, GMP, EUGMP, USFDA Services in India, Mumbai, Navi Mumbai| Contract Development and Manufacturing Organization (CDMO) WHO, GMP, EUGMP, USFDA - Services in India | Pharmaceutical Contract Manufacturing Company WHO, GMP, EUGMP, USFDA in Navi Mumbai, India | Top Pharmaceutical Product Exporters, Suppliers, Distributer WHO, GMP, EUGMP, USFDA in Mumbai